#TargetAD25
07 May - 10 May 2025
Chania, Crete
Riqiang Yan
University of Connecticut
Li-Huei Tsai
Massachusetts Institute of Technology
Peter St George-Hyslop
Columbia University
Early Bird - Expired • Talk Submission - Expired • Poster Submission - Expired • Registration & Payment Deadline - Expired
Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, affecting nearly 1 in 9 people over 65 in the world. While a great progress in translational and discovery research is excitingly being made, there still lack effective therapies for AD and related neurodegenerative diseases. This planned conference intends to bring together leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees, and to share their vision or prospects on translational or discovery research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets, new genetic association or pathways, approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries to share clinical trial results.
Mathew Blurton-Jones (University of California, Irvine)
HARNESSING STEM CELL DERIVED MICROGLIA FOR BRAIN-WIDE DELIVERY OF THERAPEUTIC PROTEINS
Guojun Bu (Hong Kong University of Science and Technology)
PATHOBIOLOGY AND THERAPEUTIC STRATEGIES AGAINST APOE IN ALZHEIMER’S DISEASE
Karen Duff (University College London)
TAUOPATHY MECHANISMS IN FTD AND AD
André Fischer (German Center for Neurodegenerative Diseases)
EXPANDING THE SPACE FOR DRUG DISCOVERY AND TRANSLATION: THE NON-CODING RNAOME IN NEURODEGENERATIVE DISEASES
René Frank (University of Leeds)
PROTEIN STRUCTURE WITHIN POSTMORTEM AD BRAIN BY FLUORESCENCE-GUIDED, IN-TISSUE CRYO-ELECTRON TOMOGRAPHY
Li Gan (Weill Cornell Medicine)
NEUROIMMUNE INTERACTIONS IN NEURODEGENERATIVE DISEASES
Michelle Gee (Eisai)
LECANEMAB DRUG DEVELOPMENT IN EARLY AD: PATH TO APPROVAL AND POTENTIAL BEYOND INITIAL INDICATION
Christian Haass (Ludwig-Maximilians University Munich)
MODULATION OF TREM2 ACTIVITY BY AN AGONISTIC ANTIBODY
Michael Heneka (University of Luxembourg)
MICROGLIA CELL FATE IN ALZHEIMER'S DISEASE
Joachim Herz (UT Southwestern Medical Center)
ApoE IN NEURONS AND MUTANT ApoE
David Holtzman (Washington University in St. Louis)
ROLE OF ApoE AND THE INNATE AND ADAPTIVE IMMUNE RESPONSE IN THE PRESENCE OF ALZHEIMER’S-LIKE PATHOLOGIES
Yadong Huang (Gladstone Institutes, University of California San Francisco)
NEURONAL ApoE4 TOXICITY IN ALZHEIMER'S DISEASE
Celeste Karch (Washington University in St. Louis)
UNDERSTANDING THE ROLE OF THE NEURO-IMMUNE AXIS IN ALZHEIMER DISEASE RESILIENCE
Yueming Li (Memorial Sloan Kettering Cancer Center)
IFITM3 MODULATES MICROGLIA STATUS IN AD
Richard Mayeux (Columbia University)
THE PATHOGENIC ROLES OF APOE IN ALZHEIMER’S DISEASE AND POTENTIAL THERAPEUTIC STRATEGIES
Inhee Mook-Jung (Seoul National University)
GUT-VAGUS NERVE-BRAIN AXIS IN ALZHEIMER'S DISEASE PATHOGENESIS
Junmin Peng (St. Jude Children's Research Hospital)
PAN-NEURODEGENERATION PROTEOMICS: NEW INSIGHTS FROM 2000 HUMAN CASES AND MOUSE MODELS
Panos Roussos (Icahn School of Medicine at Mount Sinai)
SINGLE-CELL ATLAS OF TRANSCRIPTOMIC VULNERABILITY ACROSS MULTIPLE NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASES
Michal Schwartz (Weizmann Institute of Science)
THE BRAIN-IMMUNE ECOSYSTEM: TARGETING INHIBITORY IMMUNE CHECKPOINTS TO HARNESS INNATE AND ADAPTIVE IMMUNITY TO DEFEAT ALZHEIMER’S DISEASE
Gopal Thinakaran (University of South Florida)
BIN1 RISK IN ALZHEIMER'S DISEASE: UNPACKING THE COMPLEX MECHANISMS, ONE BIN AT A TIME
Taisuke Tomita (University of Tokyo)
TARGETING NEUROINFLAMMATORY RESPONSE FOR ACCELERATED AMYLOID CLEARANCE IN ALZHEIMER DISEASE
Matheus Victor (Icahn School of Medicine at Mount Sinai)
SINGLE-CELL CORRELATES OF PSYCHOSIS IN ALZHEIMER’S DISEASE
Roberto Villaseñor (Roche Pharma Research and Early Development)
OVERCOMING THE BLOOD-BRAIN BARRIER FOR THERAPEUTIC DELIVERY WITH BRAINSHUTTLE TECHNOLOGY
Tracy Young-Pearse (Mass General Brigham and Harvard Medical School)
LEVERAGING A LARGE COHORT OF IPSC LINE FOR UNCOVERING MECHANISMS UNDERLYING ALZHEIMER’S DISEASE
Hui Zheng (Baylor College of Medicine)
GLIAL CELL-SURFACE PROTEINS IN AD
• The latest on AD genetics
• Peripheral and central immune response
• Multiomic dissection of AD
• Vulnerability and resilience
• Lipid and metabolic abnormalities in AD pathogenesis
• Novel therapeutic targets
• New Biomarkers
• AI or machine learning-based drug discovery
• Insights from molecular structures
• Brain imaging of AD brains
The significance of having this conference is to provide a unique forum for the research community focusing on translational studies geared towards therapies in AD and related neurodegenerative diseases to come together to discuss the latest advances and the future challenges in the field.
The conference is essentially open to various levels of investigators including senior, mid career and early career investigators, either in academic or industrial or clinical institutes. There will be ample opportunities for attendee to have close interactions networking and freely scientific discussions. We anticipate international representation from the US, Europe, Canada, Japan, Korea, China, and others.
Junior investigators such as graduate students or postdoctoral fellows as well as physician scientists are expected to gain knowledge on the most current therapeutic strategies in AD and the related field. The conference will also be of interest to clinical practioners seeking updates on what developments are underway in the therapeutic pipeline for AD and the scientific basis of this research pathway.
Riqiang Yan
University of Connecticut
Li-Huei Tsai
Massachusetts Institute of Technology
Peter St George-Hyslop
Columbia University
Mathew Blurton-Jones
University of California, Irvine
Guojun Bu
Hong Kong University of Science and Technology
Karen Duff
University College London
André Fischer
University Medical Center Göttingen
René Frank
University of Leeds
Li Gan
Weill Cornell Medicine
Michelle Gee
Eisai
Christian Haass
Ludwig-Maximilians University Munich
Michael Heneka
University of Luxembourg
Joachim Herz
UT Southwestern Medical Center
David Holtzman
Washington University in St. Louis
Yadong Huang
Gladstone Institutes / University of California San Francisco
Celeste Karch
Washington University in St. Louis
Yueming Li
Memorial Sloan Kettering Cancer Center
Richard Mayeux
Columbia University
Inhee Mook-Jung
Seoul National University
Priyanka Narayan
NIH
Junmin Peng
St. Jude Children's Research Hospital
Panos Roussos
Icahn School of Medicine at Mount Sinai
Michal Schwartz
Weizmann Institute of Science
Julia TCW
Boston University
Gopal Thinakaran
University of South Florida
Taisuke Tomita
University of Tokyo
Matheus Victor
Icahn School of Medicine at Mount Sinai
Roberto Villaseñor
Roche Pharma Research and Early Development
Tracy Young-Pearse
Mass General Brigham and Harvard Medical School
Hui Zheng
Baylor College of Medicine
We are please to announce we have 10 x €500 Early Career Researcher Grants available, kindly supported by BrightFocus Foundation.
To be considered, please email Rosie with:
Applications must be submitted by 13 March 2025
Avra Imperial
The Avra Imperial Hotel is situated on the picturesque bay of Kolymbari, 23km west of Chania, in Crete. Located next to the beautiful beach of Kolymbari, awarded with the EU Blue Flag, set amongst 65,000m² of fragrant lush gardens and surrounded by crystal clear turquoise waters of the Cretan sea with stunning views over the semi-mountainous peninsula, this makes for a wonderful setting for this conference.
With top class facilities including impressive swimming pools, five excellent restaurants and four vibrant bars, sports & leisure facilities, crèche & children’s club, shops, plus a rejuvenating and uniquely designed spa, there is plenty to occupy your free time whether you choose to relax and stay within the hotel or decide to venture further afield and see what Crete has to offer.
The themed Gala Night takes place on the penultimate evening of the conference with a mouth-watering feast of local cuisine, a bar and amazing local entertainment. We welcome all delegates and their accompanying persons to the Gala Night – a truly fun filled night not to be missed!
Venue Rating
★ ★ ★ ★ ★
Currency
Euro (EUR)
Address
Kolymbari 73006 Chania Crete Greece.
Nearest Airport
Chania International Airport
Hotel facilities include:
Situated 23km west of Chania, Avra Imperial Hotel is positioned in the village of Kolymbari (or Kolimbari, Kolymvari), a true Cretan seaside village, surrounded by olive goves, located on the corner formed between the northern coastline of western Crete and the Rodopos peninsula stretching towards north. The waterfront and the jetty of the new harbor, that encloses the oldest small harbor with fishing boats, is ideal for a stroll in the afternoon, overlooking the blue of the sea, on one side, and on the other, the hills and the mountains of Rodopos peninsula, rising behind the house roofs.
If you are interested in this meeting but not yet ready to register, you can sign up for updates here and our team will keep you updated regarding deadline reminders and grant opportunities relating to this meeting only.
If you're interested in sponsoring this conference please contact us.
Conference Manager
Rosie Johnson
As a family run business, our dedication runs deep. We’re committed to each other and, even more so, to every attendee’s experience, delivering a level of care and passion that’s truly unmatched.